Get 50% OFF This Monsoon!
Samsrita Labs
No Data Available
Investor Sentiment
Samsrita Labs Share price and Fundamental Analysis
Key Metrics
Stock Returns
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
Samsrita Labs Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Dr Habeebullah Life Sciences Limited was incorporated in January 25,1996. The Company is engaged into the business of research & experimental development on natural sciences and engineering, including bio pharma and hospital services also.
The Company changed its registered office from 1st Floor, Jayavant House, Azad Road, Near CBT Bhandiwad Base, Hubli - 580 020 (Karnataka) to 4-7-375/A, Television Hotel Lane, Esamia Bazar, Hyderabad - 500 027 (Telangana) vide Regional Director (SER), Hyderabad order dated 31st March, 2015.
During the year 2015, the Order was passed by Regional Director (South East Region, Hyderabad) dated 31st March, 2015 relating to Change of Registered office of the company from one state (Hubli, Karnataka) to another (Hyderabad, Telangana).M/s. Mark Corporate Advisors Private Limited (Managers to Open Offer) informed the Company and the Stock Exchanges about the Share Purchase Agreement dated Wednesday, 24 August 2016 entered by Mohammed Aejaz Habeeb (Acquirer 1), Syed Ameer Basha Paspala (Acquirer 2) and Kalidindi Krishnam Raju (Acquirer 3) with Arun Kumar Bhangadia, Promoter of the Company (Seller) for acquisition of 21,00,000 Equity Shares representing 20.47% of the Emerging Voting Capital of the M/s. PC Products India Limited (Target Company). Further, the Company in its Board Meeting held on Wednesday, 24 August 2016 has decided and approved the following:1. To acquire not less than 51% stake in M/s. Krisani Bio Sciences Private Limited by way of Swapping of Shares from the Shareholders of M/s. Krisani Bio Sciences Private Limited. 2. Allotment of 48,70,606 Equity Shares on SWAP Basis to Kalidindi Krishnam Raju (Acquirer 3 and Shareholder of M/s. Krisani Bio Sciences Private Limited) and his relatives. Pursuant to SPA and Preferential Allotment, the Acquirers have triggered the Open Offer as per SEBI (SAST) Regulations, 2011 to acquire 26,67,300 Equity Shares of Rs. 10/- each of M/s. PC Products India Limited (Target Company) representing 26% of the Emerging Equity Share Capital / Voting Capital of the Target Company.
During the year 2016-17, the Company has undergone re-structuring in terms of Capital, Change in Promoters Shareholding and Change in Management of the Company. The details are as under:a) On Wednesday, August 24, 2016, the Board of Directors of the Company approved a Preferential Allotment of 48,70,606 Equity Shares (47.48% of Paid Up Capital) on SWAP Basis to specific Shareholders of Krisani Bio-Sciences Private Limited (83:100 i.e., for eEvery 100 Equity Shares held by the Shareholders of Krisani Bio-Sciences Private Limited, 83 Equity Shares of PC Products India Limited were allotted). Out of 48,70,606 Equity Shares, 25,82,130 Equity Shares were allotted to the present Promoters of the Company i.e., K. Krishnam Raju (Acquirer 3) and balance 22,88,476 Equity Shares to the PAC's of K. Krishnam Raju (PAC's: K. Sarada Vijaya Kumari (PAC 1), K. Nirusha (PAC 2) and P. Parvathi (PAC 3); pursuant to Section 62 and other applicable provisions of Companies Act, 2013 and SEBI (ICDR) Regulations, 2009. Pursuant to the Preferential Allotment, Krisani Bio Sciences Private Limited has become the Subsidiary of the Company, holding 51.30% of its Equity.b) On Wednesday, 24th August, 2016, Arun Kumar Bhangadia (Ex/Past Promoter of the Company) entered into a Share Purchase Agreement with the Acquirers to Open Offer and Present Promoters of the Company - Dr. Mohammed Aejaz Habeeb (Acquirer 1), Dr. Syed Ameer Basha Paspala (Acquirer 2) and K. Krishnam Raju (Acquirer 3) for Sale of 21,00,000 Equity Shares. Upon completion of the aforementioned Preferential Allotment of Equity Shares and pursuant to Share Purchase Agreement; Dr. Mohammed Aejaz Habeeb (Acquirer 1), Dr. Syed Ameer Basha Paspala (Acquirer 2), K. Krishnam Raju (Acquirer 3), Kalidindi Sarada Vijaya Kumari (PAC 1), K. Nirusha (PAC 2) and P. Parvathi (PAC 3) triggered Open Offer under Regulation 3(1) and 4 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time.
The Tendering Period of Open Offer was Tuesday, 22nd November 2016 to Monday, 05th December 2016. Post Open Offer, the holding of New Promoters - Dr. Mohammed Aejaz Habeeb (Acquirer 1), Dr. Ameer Basha Paspala (Acquirer 2), K. Krishnam Raju (Acquirer 3), K. Sarada Vijaya Kumari (PAC 1), K. Nirusha (PAC 2) and P. Parvathi (PAC 3) is 76,29,030 Equity Shares (74.37% of Paid-Up Capital).
Dr. Mohammed Aejaz Habeeb (Acquirer 1), Dr. Syed Ameer Basha Paspala (Acquirer 2), K. Krishnam Raju (Acquirer 3), K. Sarada Vijaya Kumari (PAC 1), K. Nirusha (PAC 2) and P. Parvathi (PAC 3) have also acquired control over the affairs and management of the Company w.e.f. Tuesday, 27th December, 2016 and were classified as New Promoters of the Company as per Regulation 31(A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and within the meaning, definition of Promoter as defined in SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as amended from time to time. Post Open Offer and as per the Share Purchase Agreement; the Ex/Past Promoter Arun Kumar Bhangadia was re-classified under Public Category with his balance Equity Shares - 8,26,800 Equity Shares (8.06% of Paid Up Capital).
During FY2016-17 under review, the Company acquired one Subsidiary - Krisani Bio Sciences Private Limited, India.
From June 2017, the Company has only reportable segment i.e., Bio-Pharma Sector.
During Financial year 2017-18, the Paid up Capital of the Company increased from Rs 10,25,87,060/- divided into 1,02,58,706 Equity Shares of Rs 10/- each to Rs 11,75,87,060/- divided into 1,17,58,706 Equity Shares of Rs 10/- each.
The Company allotted 8,00,000 Equity Shares to Non Resident Indians (NRIs) on Preferential Basis on 17 November 2017.
The Company allotted 10,00,000 Convertible Equity Share Warrants to Promoters of the Company on Preferential Basis on 24 January 2018.The Company has allotted 27,50,000 Convertible Equity Share Warrants to Non-Promoters of the Company on Preferential Basis on 17 November 2017. Out of which, 7,00,000 Convertible Equity Share Warrants were converted into Equity Shares on 24 January 2018.
The Company converted further 4,55,000 Convertible Equity Share Warrants into Equity Shares on 04 May, 2018, leading to increase in Paid up Capital to Rs 12,21,37,060 divided into 1,22,13,706 Equity Shares of Rs 10/- each.As per the SEBI Circular No IMD/FPIC/CIR/P/2018/61 dated 5 April 2018, the Central Depository Services (India) Limited (CDSL) was appointed as the Designated Depository for the purpose of monitoring the Foreign Investment Limits in the Company.
As per SEBI Circular No SEBI/HO/CFD/DCR1/CIR/P/2018/85 dated 28 May 2018, the Central Depository Services (India) Limited (CDSL) was appointed as the Designated Depository for the purpose of System Driven Disclosures in Securities Market for the Company.
The Name of the Company was changed from PC Products India Limited to Dr. Habeebullah Life Sciences Limited vide Fresh certificate of Incorporation obtained from Registrar of Companies, Hyderabad, Telangana State, India dated 25 October, 2017.
The Company had entered into a Collaborative Agreement with its Subsidiary, Krisani Bio Sciences Private Limited for further development of Wilson Disease Molecule on revenue sharing basis on 23 August 2017.
The Company had entered into a Collaborative Agreement with its Subsidiary, Krishna Bio Sciences Private Limited for further development of Wilson Disease Molecule on revenue sharing basis on 23 August 2017.
The Company has terminated an Agreement entered with its Subsidiary, Krisani Bio Sciences Private Limited on 17 November 2017 {Initially entered on dated 25 March 2017 for further development of NASH (Fatty Liver) Molecule}
The Company has entered into a Collaborative Agreement with Centre for Liver Research And Diagnostics (CLRD) to use their land, building, equipment and other facilities to run business of Hospital, Diagnostics, Pharmacy, Stem cell and other biotechnology laboratories on revenue sharing basis dated 27 May 2017.
The Securities Exchange Board of India vide its Adjudication Order EAD-5/ SVKM /AO / 21/2017-18] dated 17 May, 2017 had imposed a penalty of Rs 4,00,000/- on the Company for non-compliance of provisions of Regulation 8(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 within the due date, during the years 2004 to 2011 at Ahmedabad Stock Exchange, Bangalore Stock Exchange and Madras Stock Exchange, where its Equity Shares were listed. The Company has paid the penal amount of Rs 4,00,000/- on Monday, 29 May 2017 to Securities Exchange Board of India towards the Adjudication Order.
The Company converted 4,55,000 Convertible Equity Share Warrants into Equity Shares on 04 May 2018 and further converted 15,95,000 equity share warrants into equity shares on 26 March 2019, during the FY 2018-19.
During FY 2018-19, the Paid up Capital of the Company increased from Rs 11,75,87,060/- divided into 1,17,58,706 Equity Shares of Rs 10/- each to Rs 138,087,060/- divided into 1,38,08,706 Equity Shares of Rs 10/- each.
The Company converted further 10,00,000 Convertible Equity Share Warrants into Equity Shares on 14th June 2019 leading to increase in paid up capital to Rs. 14,80,87,060 divided into 1,48,08,706 Equity Shares of Rs 10/- each.
Samsrita Labs Share Price
Samsrita Labs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Samsrita Labs Market Cap
Market capitalization of Samsrita Labs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Samsrita Labs is valued compared to its competitors.
Samsrita Labs PE Ratio
Samsrita Labs PE ratio helps investors understand what is the market value of each stock compared to Samsrita Labs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
Samsrita Labs PEG Ratio
The PEG ratio of Samsrita Labs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Samsrita Labs ROE (Return on Equity)
Return on Equity (ROE) measures how effectively Samsrita Labs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Samsrita Labs ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of Samsrita Labs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Samsrita Labs Total Debt
Total debt of Samsrita Labs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
Samsrita Labs Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of Samsrita Labs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
Samsrita Labs CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of Samsrita Labs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Samsrita Labs Technical Analysis
Technical analysis of Samsrita Labs helps investors get an insight into when they can enter or exit the stock. Key components of Samsrita Labs Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Samsrita Labs shares often struggle to rise above due to selling pressure.
Samsrita Labs Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Samsrita Labs ’s financial health and profitability.
Samsrita Labs Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Samsrita Labs Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
Samsrita Labs Financials
The financials of Samsrita Labs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
Samsrita Labs Profit and Loss Statements
The profit and loss statement of Samsrita Labs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Samsrita Labs .
Samsrita Labs Balance Sheet
The balance sheet presents a snapshot of Samsrita Labs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Samsrita Labs Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance/Complaints Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month